Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Total Liabilities: 2011-2024

Historic Total Liabilities for Capricor Therapeutics (CAPR) over the last 14 years, with Dec 2024 value amounting to $25.0 million.

  • Capricor Therapeutics' Total Liabilities rose 72.45% to $42.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.6 million, marking a year-over-year increase of 72.45%. This contributed to the annual value of $25.0 million for FY2024, which is 30.76% down from last year.
  • As of FY2024, Capricor Therapeutics' Total Liabilities stood at $25.0 million, which was down 30.76% from $36.1 million recorded in FY2023.
  • In the past 5 years, Capricor Therapeutics' Total Liabilities registered a high of $38.3 million during FY2022, and its lowest value of $6.4 million during FY2020.
  • Moreover, its 3-year median value for Total Liabilities was $36.1 million (2023), whereas its average is $33.2 million.
  • Per our database at Business Quant, Capricor Therapeutics' Total Liabilities skyrocketed by 284.54% in 2022 and then slumped by 30.76% in 2024.
  • Over the past 5 years, Capricor Therapeutics' Total Liabilities (Yearly) stood at $6.4 million in 2020, then surged by 55.20% to $10.0 million in 2021, then soared by 284.54% to $38.3 million in 2022, then fell by 5.68% to $36.1 million in 2023, then slumped by 30.76% to $25.0 million in 2024.